Valuation: Unicycive Therapeutics, Inc.

Market Cap 138M 121M 112M 103M 194M 13.32B 198M 1.33B 524M 6.52B 520M 508M 22.46B P/E 2026 *
-3.57x
P/E 2027 * 0.98x
Enterprise Value 138M 121M 112M 103M 194M 13.32B 198M 1.33B 524M 6.52B 520M 508M 22.46B EV / Sales 2026 *
36.4x
EV / Sales 2027 * 0.48x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 45.5%
1 day+6.44%
1 week+3.07%
Current month+14.50%
1 month-23.83%
3 months-23.50%
6 months-18.39%
Current year-6.93%
1 week 4.91
Extreme 4.9143
5.48
1 month 3.93
Extreme 3.93
8.56
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
39.4
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/5/26 Free

Chief Executive Officer

762,200 3.0201%
14/5/26 Free

Director

126,300 0.5004%
14/5/26 Free

Executive/Senior Manager

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+6.83%+3.07%+15.48%-58.37% 138M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+1.59%-6.37%+3.91%+422.90% 23.29B
+0.37%+0.26%-17.39%-14.44% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
-0.27%-1.59%+23.91%+189.73% 14B
Average -1.78%-1.53%+41.07%+160.93% 24.06B
Weighted average by Cap. -2.82%-2.20%+43.24%+144.79%

Financials

2026 *2027 *
Net sales 3.8M 3.32M 3.07M 2.83M 5.33M 366M 5.45M 36.67M 14.42M 179M 14.29M 13.97M 618M 288M 252M 233M 214M 404M 27.77B 413M 2.78B 1.09B 13.6B 1.08B 1.06B 46.82B
Net income -40.34M -35.25M -32.53M -29.98M -56.51M -3.88B -57.77M -389M -153M -1.9B -151M -148M -6.55B 186M 163M 150M 138M 261M 17.93B 267M 1.79B 706M 8.78B 699M 684M 30.23B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
18/07/26 US$5.390 +6.73% 836,879
16/07/26 US$5.050 +0.60% 858,424
15/07/26 US$5.020 -3.83% 954,472
14/07/26 US$5.220 +2.55% 599,395
13/07/26 US$5.090 -2.30% 1,175,869
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.050USD
Average target price
38.59USD
Spread / Average Target
+664.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock